It has been shown that the cholinergic system has a role in the regulation of sexual behavior (Bitran and Hull 1987; Hull et al. 1988a; 1988b; Dohanich et al. 1991) . Oxotremorine (OXO), a muscarinic receptor agonist, reduces the ejaculation threshold by decreasing in tromission frequency (IF) and ejaculation latency (EL) (Ahlenius and Larsson 1985; Bitran and Hull 1987; Hull et al. 1988a Hull et al. , 1988b and increasing the ejaculation fre quency (EF) in intact male rats (Retana et al. 1993) . As dose at which an increase of the intromission frequency and a decrease of the ejaculation frequency were observed. In the second experiment, trihexyphenidyl was administered in several doses (from 0.2 to 1.6 mglkg), before the administration of oxotremorine, a muscarinic agonist, at a dose that readily facilitates masculine sexual behavior. Trihexyphenidyl completely prevented the facilitatory effects of oxotremorine even at the smallest dose used. These results strongly suggest that the Ml muscarinic receptor subtype participates in the cholinergic facilitation of masculine sexual behavior. [Neuropsychopharmacology 9:267-270, 1993J could be expected, these facilitatory effects of OXO are completely blocked by pretreatment with the mus carinic receptor antagonist scopolamine (SCO-HCl) (Ahlenius and Larsson 1985; Hull et al. 1988b) . In addi tion, SCO-HCl by itself induces an increase in mount and intromission latency and a decrease in the percent age of sexually active males in a dose-related manner, as well as a decrease in EF (Hull et al. 1988b; Retana et al. 1993) . These data support the notion that the cholinergic system participates in the regulation of mas culine sexual behavior mainly through the muscarinic system.
During the early 1980s, it was demonstrated that the muscarinic receptor population could be subdivided into at least two major subclasses according to its affmity for the antagonist pirenzepine (Hammer et al. 1980; Hammer and Giachetti 1982) . Since then, drugs acting at cholinergic synapsis have been analyzed for their different affinity with a specilic sub population of mus carinic receptors (for review, see Wolfe 1989) .
Trihexyphenidyl (TRI) is a muscarinic antagonist that has been used for years as coadjuvant in the treat ment of movement disorders in humans (Burke et al. 1986; Doshay and Constable 1949; Rubinstein 1978) . Tri hexyphenidyl is a selective blocker of the M1 muscarinic receptor subtype (Avissar and Schreiber 1989; D6rje et al. 1991; Giachetti et al. 1986; Lambrecht et al. 1988; Tien and Wallace 1985) and some reports suggest that it read ily crosses the blood-brain barrier (Goyal 1989; McInnis and Petursson 1984; Valevski et al. 1992) .
In the present study, we analyze the possible par ticipation of the M1 muscarinic receptor subtype both in the regulation of masculine sexual behavior and in the mediation of the facilitatory effects of OXO on mas culine sexual behavior.
METHODS
Male Wistar adult rats weighing between 300 and 350 g were housed, &ve per cage (50 x 30 x 20 cm), under constant temperature and humidity conditions. The colony room was maintained on a 12-hour/12-hour re verse light-dark cycle (lights off: 9 AM). Food and wa ter were available ad libitum.
To assess the effect of TRI by itself on masculine sexual behavior, the following groups were tested. Group A (n = 10) received three lower doses (0.1,0.2, and 0.4 mg/kg) of TRI or a vehicle (distilled water) con trol injection. Group B (n = 10) received four higher doses (0.8, 1.6,3.2, and 6.4 mg/kg) or a vehicle control injection.
To assess the interaction between the muscarinic M1 blockade and the facilitatory effect of OXO, the fol lowing groups were tested. Group C (n = 10) animals were pretreated with the muscarinic peripheral blocker SCO-MBr (3 mg/kg) 15 minutes before the administra tion of OXO (0.4 mg/kg) or saline. This experiment was performed to corroborate the facilitatory effects of OXO (Ahlenius and Larsson 1985; Retana et al. 1993) . Group D (n = 10) animals received four different doses of TRI (0.2,0.4, 0.8, and 1.6 mg/kg) 15 minutes before the ad ministration of OXO (0.4 mg/kg).
Antagonists injections were made 45 minutes be fore the behavioral tests. This time period was selected because of TRI pharmacokinetics (Burke and Fahn, 1985) and to compare its effects with those of the unspecifIc muscarinic blocker SCO-HCl. The sequence of injections was randomized and a I-week period elapsed between observations.
Behavioral testing was performed under dim red light illumination and began 3 hours after the onset of the dark phase of the cycle. Masculine sexual behavior was assessed by placing the male in a plexiglass arena (45 cm in diameter) for 5 minutes before a stimulus receptive female was presented. Female rats were NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.4 brought into sexual receptivity by sequential treatment with estradiol benzoate (5 J.1g/.1 mI oil, subcutaneously, once daily). To avoid stimulus habitation, the female rat was changed every 5 minutes (Wilson et al. 1963) . After presentation of the female, the tests lasted 30 minutes. All subjects were previously tested and only those that displayed at least one ejaculation were in cluded in the study. The following parameters were recorded: mount (ML), intromission (IL) and ejacula tion (EL) latencies, mount (MF), intromission (IF), and ejaculation (EF) frequencies; and postejaculatory inter val (PEl). Also, the following indexes were obtained: hit rate (HR), which was equal to (number of intromis sions/number of intromissions plus number of mounts); average interintromission interval (AlII) (ejaculation latency/number of intromissions); average intercopula tory interval (AICI) (ejaculation latency/number of in tromissions plus number of mounts). A full description of masculine sexual behavior parameters has been detailed elsewhere (Sachs and Meisel 1988) .
Estradiol benzoate was purchased from Aldrich Chemical Co. (Milwaukee, WI). Scopolamine methyl bromide (SCO-MBr), oxotremorine sesquifumarate (OXO) and trihexyphenidyl hydrochloride (TRI) were obtained from Sigma Chemical Co. (St. Louis, MO). Estradiol was dissolved in methanol and resuspended in oil. It was subcutaneously administered in a volume of .05 mI. Trihexyphenidyl was dissolved in distilled water. Both SCO-MBr and OXO were dissolved in a 0.9% saline solution. These drugs were intraperitoneally administered in a volume of 0.2 mI.
Statistical analysis was performed using the Krush aI-Wallis one-way analysis of variance followed by the Mann-Whitney U-test for comparisons between treat ments and control.
RESULTS
Trihexyphenidyl did not modify most of the recorded parameters of masculine sexual behavior when applied systemically in a wide range of doses. When compared to the results obtained with vehicle administration, onl y the highest dose used (6.4 mg/kg) elicited signifIcant changes, and those were restricted to an increase of IF in the &rst ejaculatory series and a decrease of the EF.
As it has been previously reported (Ahlenius and Larsson 1985; Retana et al. 1993) , OXO effects were not prevented by the previous administration of the periph eral muscarinic antagonist SCO-MBr. The administra tion of OXO induced a decrease of IF and in EL, as well as an increase in EF.
Concerning the antagonistic actions of the Ml blocker, as can be seen in Figure lA 
"'ann Whitney U-teat compared to control.
• p (0.05 . .. P (0.01. _ P (0.005. Figure 1 . The signifIcant decrease of intromission frequency (A) and ejaculation latency (B) induced by the administra tion of OXO (0.4 mg/kg) was prevented with all doses of TRl (from 0.2 to 1.6 mg/kg) previously injected, but not by scopola mine methyl bromide (3 mg/kg). The signifIcant increase of ejaculatory frequency induced by OXO (C) was inhibited by the previous administration of TRl only at the highest dose used (1.6 mg/kg), but not by SCO-MBr. Vehicle injection does not modify any of these parameters. Data are expressed as mean ± SEM M1 Receptor Subtype and Sexual Behavior 269 used. A similar inhibition of the facilitatory effects of OXO was also observed for the EL (Figure 18 ). On the other hand, low doses of TRI were not capa ble of suppressing the increase in EF elicited by OXO (Figure lC ) . Blockade of this effect was obtained only with the highest dose of TRI (1.6 mg/kg) used.
DISCUSSION
The present results conii.rm previous evidence that the cholinergic system is implicated in the regulation of sexual behavior in male rats, mainly through musca rinic receptors as indicated by the facilitatory effects in duced by OXO administration. Additionally, these data strongly suggest the notion that this cholinergic facili tation of masculine sexual behavior is mediated through the Ml muscarinic receptor subtype. When the Ml selective antagonist TRI was administered before the muscarinic agonist OXO, the facilitatory effects of this agonist on masculine sexual behavior were almost com pletely prevented, even with the smallest dose of TRI used.
On the other hand, it seems that selective block ade of the central and peripheral muscarinic Ml recep tor subtype by itself is incapable of inducing any notice able modiii.cations in the masculine sexual behavior parameters recorded. At a very high dose, however, a signiii.cant increase of IF was observed as well as a decrease in EF, which correlates exactly with the de crease of IF and the increase of EF observed with OXO, supporting the notion that intromission regulation and ejaculatory potential is linked to the Ml subtype.
There is evidence that pirenzepine, the prototype Ml muscarinic receptor antagonist, can reverse central OXO-induced effects on learning (Witkin et al. 1988) . These data also support the Ml mediation of OXO effects.
The unspeciii.c muscarinic antagonist SCO-HCl causes a decrease in the percentage of sexually active males and a marked increase in mount or intromission latencies (Ahlenius and Larsson 1985; Retana et al . 1993) . By itself, TRI did not induce those effects. These data open the possibility that the effects of SCO-HCl on male sexual behavior could be mediated by a differ ent muscarinic receptor subtype. Thus, the effects that Ml and M2 agonists and M2 antagonists could produce on male sexual behavior remain to be studied to fur ther understand the muscarinic mechanisms that regu late masculine sexual behavior.
